Table S2. Risk factors for fatigue in 336 COVID-19 patients at six months follow-up

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | All | Fatigue | No fatigue |  |  |
| Characteristic | **n** | **% (n)** | **% (n)** | **OR (CI)** | **aOR(CI)** |
|  | ***293*** | ***n=108*** | ***n=185*** |  |  |
| *Baseline features* |  |  |  |  |  |
| Female sex | 150 | 43% (64) | 57% (86) | 1.67 (1.04-2.72)\* | 1.83 (1.07-3.16)\* |
| - Male | 143 | 31% (44) | 69% (99) | 1 |  |
| Age, median (IQR) | 293 | 51.5 (37-61) | 45 (30-57) | 1.02 (1.00-1.03)\* | 1.00 (0.98-1.02) |
| Age categories |  |  |  |  |  |
| - 16-30 years | 65 | 26% (17) | 74% (48) | 1 |  |
| - 31-45 years | 68 | 35% (24)) | 65% (44) | * 1. 0.74-3.28) |  |
| - 46-60 years | 88 | 40% (35) | 60% (53) | * 1. (0.94-3.81) |  |
| - Over 60 years | 72 | 44% (32) | 56% (40) | 2.26 (1.11-4.73)\* |  |
| BMI, median (IQR) | 293 | 25.3 (23.1-27.7) | 24.7 (23.0-27.2) | 1.03 (0.97-1.09) | 0.99 (0.92-1.07) |
| Any comorbidity | 133 | 47% (62) | 53% (71) | 2.16 (1.34-3.51)\* |  |
| - None | 160 | 29% (46) | 71% (114) | 1 |  |
| Asthma, COPD† | 37 | 62% (23) | 38% (14) | * 1. 1.62-6.75)\* | 2.40 (1.11-5.30)\* |
| - No lung disease | 256 | 33% (85) | 67% (171) | 1 |  |
| CHD | 21 | 62% (13) | 38% (8) | * 1. 1.21-7.56)\* | 2.65 (0.89-8.29) |
| - No CHD | 272 | 35% (95) | 65% (177) | 1 |  |
| Hypertension | 34 | 50% (17) | 50% (17) | * 1. (0.90-3.79) |  |
| - No hypertension | 259 | 35% (91) | 65% (168) | 1 |  |
| Diabetes | 13 | 46% (6) | 54% (7) | * 1. (0.40-5.39) |  |
| - No diabetes | 280 | 36% (102) | 64% (178) | 1 |  |
| CKD | 1 | 100% (1) | 0% (0) | NA |  |
| - No CKD | 292 | 37% (107) | 63% (185) | 1 |  |
| Immunosuppression | 10 | 60% (6) | 40% (4) | * 1. (0.61-13.09) |  |
| - None | 283 | 36% (102) | 64% (181) | 1 |  |
| Smoker‡ | 95 | 41% (39) | 59% (56) | * 1. 0.79-2.17) |  |
| - Never smoked | 196 | 35% (68) | 65% (128) | 1 |  |
| - NA | 2 | 50% (1) | 50% (1) |  |  |
|  |  |  |  |  |  |
| *Initial illness* |  |  |  |  |  |
| Symptomatic disease | 249 | 37% (93) | 63% (156) | * 1. (0.51-5.30) |  |
| - Asymptomatic | 15 | 27% (4) | 73% (11) |  |  |
| - NA | 29 | 38% (11) | 62% (18) |  |  |
| Hospitalised | 62 | 63% (39) | 37% (23) | 3.98 (2.21 – 7.16)\* |  |
| - Outpatient | 231 | 30% (69) | 70% (162) | 1 |  |
| Days in hospital, mean (CI) | 293 | 2.9 (1.6-4.3) | 1.6 (0.5-2.7) | 1.02 (0.99-1.06) | 0.97 (0.91-1.02 |
| Severity of illness |  |  |  |  |  |
| - Asymptomatic | 15 | 27% (4) | 73% (11) | * 1. (0.23-2.57) |  |
| - Outpatients | 216 | 30% (65) | 70% (151) | 1 |  |
| - Hospitalised | 28 | 61% (17) | 39% (11) | 3.59 (1.61-8.31)\* |  |
| - Need for oxygen | 24 | 71% (17) | 29% (7) | 5.64 (2.32-15.19)\* |  |
| - Need for NIV | 4 | 75% (3) | 25% (1) | 6.97 (0.87-142.33) |  |
| - Need for respirator | 6 | 33% (2) | 67% (4) | 1.16 (0.16-6.10) |  |
| Severity, mean (CI) § | 293 | 3.0 (2.7-3.3) | 2.4 (2.2-2.5) | 1.51 (1.24-1.87)\* | 1.86 (1.30-2.73)\* |
| Spike antibodies¶ | 293 | 4.1 (3.9-4.2) | 3.7 (3.6-3.9) | 1.71 (1.25-2.39)\* | 1.37 (0.93-2.09) |
| Microneutralising antibodies¶ | 283 | 2.2 (2.1-2.4) | 1.9 (1.8-2.0) | 1.78 (1.27-1.51)\* |  |
|  |  |  |  |  |  |
| *Acute complications* |  |  |  |  |  |
| ARF | 8 | 38% (3) | 62% (5) | * 1. (0.24-4.39) |  |
| - None | 285 | 37% (105) | 63% (180) | 1 |  |
| Hypotension | 3 | 100% (3) | 0% (0) | NA |  |
| - None | 290 | 36% (105) | 64% (185) | 1 |  |
| Lung failure | 23 | 52% (12) | 48% (11) | * 1. (0.84-4.65) |  |
| - None | 270 | 36% (96) | 64% (174) | 1 |  |
| Antibiotic use | 31 | 55% (17) | 45% (14) | * 1. (1.08-4.84)\* | 0.39 (0.10-1.51) |
| - None | 62 | 35% (91) | 65% (171) | 1 |  |

OR: odds ratio, aOR: adjusted odds ratio from multivariable analysis by binomial logistic regression, CI: 95% confidence interval, BMI: body mass index, COPD: chronic obstructive lung disease, CHD: chronic heart disease, CKD: chronic kidney disease, NIV: non-invasive respiratory support, ARF: acute renal failure. Variables were assessed by Poisson regression.

\*Statistical significance at the level p<0.05

†Twenty of 23 had asthma

‡Current or prior smoker. §Severity on an eight-category ordinal scale. ¶ Means and 95% confidence interval of Log10 convalescent antibody titres 2 months after initial illness.